Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Breast Cancer Retrieve available abstracts of 190 articles: HTML format

Single Articles

July 2025
1. TSUKIOKI T, Takata N, Dennis SR, Terata K, et al
   Japanese translation of the Functional Assessment of Cancer Therapy-Breast + 4 (FACT-B + 4) following international guidelines: a verification of linguistic validity.
   Breast Cancer. 2025;32:773-782.
   PubMed     Abstract available
   
   
   
2. SOWA Y, Seki H, Abe H, Komiya T, et al
   Influence of age on patient decision regret following breast reconstruction: a multicenter collaborative study in Japan.
   Breast Cancer. 2025;32:826-833.
   PubMed     Abstract available
   
   
   
3. HARA Y, Tan PH, Foschini MP, Yano H, et al
   Polymorphous adenocarcinoma-like tumor of the breast: the first case report from Japan.
   Breast Cancer. 2025;32:867-873.
   PubMed     Abstract available
   
   
   
4. TAKANO Y, Mizuno K, Iwase M, Morita S, et al
   Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.
   Breast Cancer. 2025;32:816-825.
   PubMed     Abstract available
   
   
   June 2025
5. KUL KOPRULU T, Aras S, Erkal Cam B, Kara A, et al
   Comparison of transcriptome profiles of radiotherapy beams on MCF-7 breast cancer xenografts.
   Breast Cancer. 2025 Jun 27. doi: 10.1007/s12282-025-01735.
   PubMed     Abstract available
   
   
   
6. HUANG M, Zhang J, Yan C, Ling R, et al
   KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.
   Breast Cancer. 2025 Jun 24. doi: 10.1007/s12282-025-01737.
   PubMed     Abstract available
   
   
   
7. YOSHINAMI T, Takano Y, Ozaki Y, Kajiwara Y, et al
   Correction: Real?world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first? or second?line treatment for hormone receptor-positive, HER2?negative advanced or met
   Breast Cancer. 2025 Jun 23. doi: 10.1007/s12282-025-01736.
   PubMed    
   
   
   
8. SANLI AN, Turan B, Tekcan Sanli DE, Aydogan F, et al
   Marital status as an independent prognostic factor in male breast cancer: a SEER-based cohort study.
   Breast Cancer. 2025 Jun 16. doi: 10.1007/s12282-025-01733.
   PubMed     Abstract available
   
   
   
9. LUO Y, Saibaidula Y, Sun Y, Ye Y, et al
   Treatment and prognosis of patients with hormone receptor-low positive (1%-10%) breast cancer: a retrospective propensity score-matched analysis.
   Breast Cancer. 2025 Jun 9. doi: 10.1007/s12282-025-01730.
   PubMed     Abstract available
   
   
   
10. AKITA Y, Velaga R, Iwase M, Shimada S, et al
    Correction to: Prognostic impact of ER?staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
    Breast Cancer. 2025 Jun 9. doi: 10.1007/s12282-025-01729.
    PubMed    
    
    
    
11. ISHITOBI M, Yoshida A, Kimura Y, Sagara Y, et al
    Impact of margin status on ipsilateral breast tumor recurrence after breast-conserving treatment for patients with breast cancer who received neoadjuvant chemotherapy: a retrospective multi-institutional study of 1813 cases.
    Breast Cancer. 2025 Jun 9. doi: 10.1007/s12282-025-01732.
    PubMed     Abstract available
    
    
    
12. TURNA M, Yildirim BA, Numanoglu C, Gul ME, et al
    Stereotactic radiosurgery for HER2-positive breast cancer brain metastases: prognostic factors and the evolving role of anti-HER2 therapies.
    Breast Cancer. 2025 Jun 8. doi: 10.1007/s12282-025-01731.
    PubMed     Abstract available
    
    
    
13. XU G, Zhao K, Zhou X, Zhang L, et al
    Clinical application of 90-gene expression test in a patient with occult breast cancer: a case report and literature review.
    Breast Cancer. 2025 Jun 5. doi: 10.1007/s12282-025-01728.
    PubMed     Abstract available
    
    
    
14. PENG G, Lee G, Kim S, Chen QY, et al
    Meta-analysis of smoking and breast cancer risk: by age of smoking initiation.
    Breast Cancer. 2025 Jun 3. doi: 10.1007/s12282-025-01715.
    PubMed     Abstract available
    
    
    May 2025
15. SHIEN T, Nogi H, Ogiya A, Ishitobi M, et al
    Immediate breast reconstruction surgery for breast cancer: current status and future directions.
    Breast Cancer. 2025 May 26. doi: 10.1007/s12282-025-01723.
    PubMed     Abstract available
    
    
    
16. IMOTO S, Yasojima H, Nagashima T, Onishi T, et al
    Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.
    Breast Cancer. 2025 May 25. doi: 10.1007/s12282-025-01726.
    PubMed     Abstract available
    
    
    
17. ISOGAI A, Terada M, Wanifuchi-Endo Y, Fujita T, et al
    Optimal patient population for adjuvant S-1 therapy in hormone receptor-positive, HER2-negative early breast cancer.
    Breast Cancer. 2025 May 24. doi: 10.1007/s12282-025-01722.
    PubMed     Abstract available
    
    
    
18. COOPER J, Airstone B, Beaman E, Carollo E, et al
    Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer.
    Breast Cancer. 2025 May 24. doi: 10.1007/s12282-025-01724.
    PubMed     Abstract available
    
    
    
19. FUSHIMI A, Terada M, Tahara R, Nakazawa Y, et al
    Assessing the quality of Japanese online breast cancer treatment information using large language models: a comparison of ChatGPT, Claude, and expert evaluations.
    Breast Cancer. 2025 May 21. doi: 10.1007/s12282-025-01719.
    PubMed     Abstract available
    
    
    
20. YOSHINAMI T, Takano Y, Ozaki Y, Kajiwara Y, et al
    Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic brea
    Breast Cancer. 2025 May 20. doi: 10.1007/s12282-025-01713.
    PubMed     Abstract available
    
    
    
21. YOSHINAMI T, Shibata N, Tamaki K, Ishimaru K, et al
    Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan.
    Breast Cancer. 2025 May 19. doi: 10.1007/s12282-025-01714.
    PubMed     Abstract available
    
    
    
22. AKITA Y, Velaga R, Iwase M, Shimada S, et al
    Prognostici of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
    Breast Cancer. 2025 May 18. doi: 10.1007/s12282-025-01716.
    PubMed     Abstract available
    
    
    
23. LIU W, Gao F, Ma N, Zhang H, et al
    Effects of CBT-based interventions on health outcomes in breast cancer patients: a systematic review and Meta-analysis.
    Breast Cancer. 2025 May 14. doi: 10.1007/s12282-025-01711.
    PubMed     Abstract available
    
    
    
24. USHIGUSA T, Hirakawa N, Kanomata N
    Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol.
    Breast Cancer. 2025 May 13. doi: 10.1007/s12282-025-01721.
    PubMed     Abstract available
    
    
    
25. MIYASHITA M, Kumamaru H, Hayashi N, Kimura F, et al
    Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan.
    Breast Cancer. 2025 May 12. doi: 10.1007/s12282-025-01718.
    PubMed     Abstract available
    
    
    
26. TAGUCHI M, Takada M, Jiaxi H, Fukui Y, et al
    Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective study.
    Breast Cancer. 2025 May 10. doi: 10.1007/s12282-025-01712.
    PubMed     Abstract available
    
    
    
27. LU ZZ, Guo LF, Zhou J, Wu SG, et al
    A nomogram to predict the benefit of postmastectomy radiotherapy in breast cancer with nodal micrometastases.
    Breast Cancer. 2025 May 7. doi: 10.1007/s12282-025-01717.
    PubMed     Abstract available
    
    
    
28. KAKIMI K, Sugie T
    Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.
    Breast Cancer. 2025 May 6. doi: 10.1007/s12282-025-01707.
    PubMed     Abstract available
    
    
    
29. VENKATARAMAN J, Mokbel K
    Limitations in translating in vitro ADSC findings to clinical breast cancer risk.
    Breast Cancer. 2025 May 5. doi: 10.1007/s12282-025-01710.
    PubMed    
    
    
    
30. TAKAHASHI M, Minoura Y, Den H, Nomizu T, et al
    Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database.
    Breast Cancer. 2025 May 5. doi: 10.1007/s12282-025-01704.
    PubMed     Abstract available
    
    
    
31. SOEDA I, Shibata M, Inaishi T, Ichikawa T, et al
    ATPase copper transporting beta attenuates malignant features with high expression as an indicator of favorable prognosis in breast cancer.
    Breast Cancer. 2025 May 2. doi: 10.1007/s12282-025-01705.
    PubMed     Abstract available
    
    
    
32. LAM MC, Grufman V, Fertsch S, Recker F, et al
    Effects of breast size on breast reconstruction in BRCA mutation carriers and genetic high-risk patients after bilateral mastectomy.
    Breast Cancer. 2025;32:582-595.
    PubMed     Abstract available
    
    
    
33. WU Q, He J, Herrler T, Yu B, et al
    Adipose-derived stem cells enhance the tumorigenic potential of pre-malignant breast epithelial cells through paracrine activation of PI3K-AKT pathway.
    Breast Cancer. 2025;32:552-565.
    PubMed     Abstract available
    
    
    
34. MATSUBARA Y, Suganuma N, Nakamoto S, Kikawa Y, et al
    Repeated sentinel lymph node biopsy for local recurrence after breast-conserving surgery.
    Breast Cancer. 2025;32:512-519.
    PubMed     Abstract available
    
    
    April 2025
35. KONISHI T, Kumamaru H, Niikura N, Sagara Y, et al
    Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status.
    Breast Cancer. 2025 Apr 21. doi: 10.1007/s12282-025-01698.
    PubMed     Abstract available
    
    
    
36. USHIGUSA T, Yoshida A, Kanomata N
    Reply to the letter to the editor "Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients".
    Breast Cancer. 2025 Apr 13. doi: 10.1007/s12282-025-01703.
    PubMed    
    
    
    
37. DING X, Zhu M, Kan H, Wang Q, et al
    Relationship between psychological resilience and cognitive function on breast cancer chemotherapy patients: a person-centered method.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01697.
    PubMed     Abstract available
    
    
    
38. JO A, Iwamoto T, Suzuki Y, Ogata R, et al
    Validation of the Symptom Illustration Scale within an electronic Patient-Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01702.
    PubMed     Abstract available
    
    
    
39. WATANUKI R, Sakai H, Takehara Y, Yoshida A, et al
    Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01700.
    PubMed     Abstract available
    
    
    
40. MIZUTA M, Okumura M, Inoue J, Ueda Y, et al
    Association between preoperative grip strength and postoperative upper extremity impairments in patients with breast cancer: a retrospective cohort study.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01699.
    PubMed     Abstract available
    
    
    
41. NAGAI SE, Hattori M, Yoshinami T, Masuda H, et al
    Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
    Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01689.
    PubMed     Abstract available
    
    
    
42. MAN V, Duan J, Luk WP, Fung LH, et al
    Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes.
    Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01692.
    PubMed     Abstract available
    
    
    
43. SONG N, Yang K, Li Y
    Constructing shared genetic architecture between bioavailable testosterone and luminal A breast cancer in female.
    Breast Cancer. 2025 Apr 3. doi: 10.1007/s12282-025-01696.
    PubMed     Abstract available
    
    
    
44. UEMATSU M, Nakajima H, Miyake H, Wakabayashi M, et al
    Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.
    Breast Cancer. 2025 Apr 2. doi: 10.1007/s12282-025-01694.
    PubMed     Abstract available
    
    
    March 2025
45. GARCIA-CHICO C, Lopez-Ortiz S, Lorenzo-Crespo C, Pinto-Fraga J, et al
    Wrapping up the evidence: bandaging in breast cancer-related lymphedema-a systematic review and meta-analysis.
    Breast Cancer. 2025 Mar 31. doi: 10.1007/s12282-025-01693.
    PubMed     Abstract available
    
    
    
46. TOI M
    Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer.
    Breast Cancer. 2025 Mar 27. doi: 10.1007/s12282-025-01695.
    PubMed    
    
    
    
47. SOTA Y, Seno S, Naoi Y, Honma K, et al
    IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses.
    Breast Cancer. 2025 Mar 24. doi: 10.1007/s12282-025-01687.
    PubMed     Abstract available
    
    
    
48. WANG SJ, Feng X, Zhang W, Fang H, et al
    Specific types of anxiety regarding radiation therapy in patients with breast cancer: a longitudinal study.
    Breast Cancer. 2025 Mar 23. doi: 10.1007/s12282-025-01690.
    PubMed     Abstract available
    
    
    
49. USHIGUSA T, Hirakawa N, Kajiura Y, Yoshida A, et al
    Correction: Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.
    Breast Cancer. 2025 Mar 17. doi: 10.1007/s12282-025-01688.
    PubMed    
    
    
    
50. DONG C, Sun Y, Xu X, Li H, et al
    c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERalpha: the central role of miR-152 and miR-148a.
    Breast Cancer. 2025 Mar 3. doi: 10.1007/s12282-025-01683.
    PubMed     Abstract available
    
    
    
51. SATO K, Fuchikami H, Takeda N, Natsume N, et al
    Long-term local control and cosmesis of perioperative interstitial brachytherapy for partial breast irradiation following breast-conserving surgery.
    Breast Cancer. 2025;32:447-455.
    PubMed     Abstract available
    
    
    
52. FARHAT J, Sakai H, Tsurutani J
    Management of nausea and vomiting induced by antibody-drug conjugates.
    Breast Cancer. 2025;32:278-285.
    PubMed     Abstract available
    
    
    
53. NAKATSUKA K, Karakawa R, Yano T
    Color differences of skin paddles using the free flap for autologous breast reconstruction in Asian patients.
    Breast Cancer. 2025;32:306-313.
    PubMed     Abstract available
    
    
    February 2025
54. WU SI, Chen VC, Hsu YH, Tzang BS, et al
    Contemporaneous changes in cytokines and cognitive function during chemotherapy in patients with breast cancer: a prospective follow-up study.
    Breast Cancer. 2025 Feb 25. doi: 10.1007/s12282-025-01668.
    PubMed     Abstract available
    
    
    
55. NATORI K, Igeta M, Morimoto T, Nagahashi M, et al
    Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters.
    Breast Cancer. 2025 Feb 20. doi: 10.1007/s12282-025-01678.
    PubMed     Abstract available
    
    
    
56. ANDO Y, Masuda T, Hayashi N, Kosai K, et al
    SET-binding protein 1 (SETBP1) suppresses cell proliferation in estrogen receptor-positive breast cancer.
    Breast Cancer. 2025 Feb 20. doi: 10.1007/s12282-025-01667.
    PubMed     Abstract available
    
    
    
57. KAWASHIMA K, Narui K, Nishikawa A, Sasamoto M, et al
    The impact of axillary lymph-node dissection omission on adjuvant abemaciclib eligibility in HR-positive, HER2-negative breast cancer with positive sentinel lymph nodes.
    Breast Cancer. 2025 Feb 20. doi: 10.1007/s12282-025-01684.
    PubMed     Abstract available
    
    
    
58. KIM SH, Oh JM, Kim YJ, Kim J, et al
    Postoperative cholesterol changes as early predictors of breast cancer-related lymphedema: a retrospective cohort study.
    Breast Cancer. 2025 Feb 18. doi: 10.1007/s12282-025-01682.
    PubMed     Abstract available
    
    
    
59. NISHIMURA R, Sagara Y, Mitsueda R, Taira T, et al
    A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer.
    Breast Cancer. 2025 Feb 18. doi: 10.1007/s12282-025-01677.
    PubMed     Abstract available
    
    
    
60. RIZK M, Mokbel K
    Refining the role of surgery in de novo stage IV breast cancer: the need for biomarkers and mechanistic insights.
    Breast Cancer. 2025 Feb 17. doi: 10.1007/s12282-025-01681.
    PubMed    
    
    
    
61. NAKAYAMA S, Iwamoto T, Araki K, Narui K, et al
    A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy.
    Breast Cancer. 2025 Feb 10. doi: 10.1007/s12282-025-01680.
    PubMed     Abstract available
    
    
    
62. HARA A, Ozaki A, Murakami M, Saito H, et al
    Breast cancer screening rates and influencing factors among LGBTQ groups in Japan.
    Breast Cancer. 2025 Feb 8. doi: 10.1007/s12282-025-01669.
    PubMed     Abstract available
    
    
    
63. NAGAHASHI M, Kumamaru H, Kinukawa N, Iwamoto T, et al
    Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression.
    Breast Cancer. 2025 Feb 6. doi: 10.1007/s12282-025-01671.
    PubMed     Abstract available
    
    
    
64. TOKUNAGA E, Koi Y, Tajiri W, Koga C, et al
    The impact of breast surgery and systemic therapy on the survival of patients with de novo stage IV breast cancer.
    Breast Cancer. 2025 Feb 2. doi: 10.1007/s12282-025-01675.
    PubMed     Abstract available
    
    
    January 2025
65. ONDER T, Karacin C
    NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life.
    Breast Cancer. 2025 Jan 31. doi: 10.1007/s12282-025-01676.
    PubMed     Abstract available
    
    
    
66. PARK MS, Cho EH, Youn Y, Do IG, et al
    Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients.
    Breast Cancer. 2025 Jan 31. doi: 10.1007/s12282-025-01673.
    PubMed     Abstract available
    
    
    
67. ALTUNDAG K
    Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.
    Breast Cancer. 2025 Jan 29. doi: 10.1007/s12282-025-01672.
    PubMed    
    
    
    
68. NAGAHASHI M, Ishikawa E, Nagai T, Kanaoka H, et al
    Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer. 2025 Jan 14. doi: 10.1007/s12282-025-01665.
    PubMed     Abstract available
    
    
    
69. IWABUCHI E, Miki Y, Xu J, Kanai A, et al
    Tetraspanins CD63 and CD81 as potential prognostic biomarkers in breast cancer.
    Breast Cancer. 2025 Jan 14. doi: 10.1007/s12282-025-01666.
    PubMed     Abstract available
    
    
    
70. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
    Impact of breast size and composition on the accuracy of mammography and ultrasonography in breast cancer screening.
    Breast Cancer. 2025 Jan 2. doi: 10.1007/s12282-024-01664.
    PubMed     Abstract available
    
    
    
71. TAKAHASHI K, Kagami Y, Yoshimura R, Morota M, et al
    Prospective study of once-daily accelerated partial breast irradiation using 3-dimensional conformal external beam radiotherapy for Japanese women: 12-year outcomes, toxicity, and cosmesis.
    Breast Cancer. 2025;32:197-207.
    PubMed     Abstract available
    
    
    
72. NAKAYAMA S, Yoshizawa A, Tsurutani J, Yoshimura K, et al
    Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).
    Breast Cancer. 2025;32:177-185.
    PubMed     Abstract available
    
    
    
73. SUNG YN, Jeon T, Lee JY, Oh J, et al
    Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.
    Breast Cancer. 2025;32:186-196.
    PubMed     Abstract available
    
    
    
74. BEHRENS AS, Huebner H, Haberle L, Stamminger M, et al
    Comparative assessment of breast volume using a smartphone device versus MRI.
    Breast Cancer. 2025;32:166-176.
    PubMed     Abstract available
    
    
    
75. GARG S, Rai G, Singh S, Gauba P, et al
    An insight into the role of innate immune cells in breast tumor microenvironment.
    Breast Cancer. 2025;32:79-100.
    PubMed     Abstract available
    
    
    
76. TAN E, Chong J, Pua U, Tan EY, et al
    Local recurrence and residual tumor rates following cryoablation for small early-stage breast cancers: systemic review and meta-analysis.
    Breast Cancer. 2025;32:69-78.
    PubMed     Abstract available
    
    
    December 2024
77. USHIGUSA T, Hirakawa N, Kajiura Y, Yoshida A, et al
    Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.
    Breast Cancer. 2024 Dec 27. doi: 10.1007/s12282-024-01662.
    PubMed     Abstract available
    
    
    
78. LIU P, Liu D, Zhao C, Wei Y, et al
    Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study.
    Breast Cancer. 2024 Dec 27. doi: 10.1007/s12282-024-01663.
    PubMed     Abstract available
    
    
    
79. PARK YS, Jang SI, Shin J, Nam CM, et al
    Factors associated with post acute care utilization after mastectomy for breast cancer patients.
    Breast Cancer. 2024 Dec 19. doi: 10.1007/s12282-024-01659.
    PubMed     Abstract available
    
    
    
80. KAKUMOTO A, Jamiyan T, Koyanagi A, Kuroda H, et al
    Prognostic impact of tumor?associated stroma in triple-negative breast cancer.
    Breast Cancer. 2024 Dec 18. doi: 10.1007/s12282-024-01661.
    PubMed     Abstract available
    
    
    
81. BATOOL Z, Kamal MA, Shen B
    Evidence-based advancements in breast cancer genetic counseling: a review.
    Breast Cancer. 2024 Dec 17. doi: 10.1007/s12282-024-01660.
    PubMed     Abstract available
    
    
    
82. HATTORI M
    Role of circulating tumor cells in breast cancer.
    Breast Cancer. 2024 Dec 10. doi: 10.1007/s12282-024-01651.
    PubMed     Abstract available
    
    
    
83. GAMBA G, Colonetti T, Uggioni MLR, Elibio LU, et al
    Gut microbiota and breast cancer: systematic review and meta-analysis.
    Breast Cancer. 2024 Dec 9. doi: 10.1007/s12282-024-01658.
    PubMed     Abstract available
    
    
    
84. AOYAMA Y, Ozaki Y, Kizawa R, Masuda J, et al
    Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.
    Breast Cancer. 2024 Dec 7. doi: 10.1007/s12282-024-01657.
    PubMed     Abstract available
    
    
    
85. MORITA M, Tsunashima R, Yoshinami T, Ishida M, et al
    A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients.
    Breast Cancer. 2024 Dec 4. doi: 10.1007/s12282-024-01656.
    PubMed     Abstract available
    
    
    November 2024
86. OTANI Y, Tanaka A, Maekawa M, Pena T, et al
    The role of C1orf50 in breast cancer progression and prognosis.
    Breast Cancer. 2024 Nov 28. doi: 10.1007/s12282-024-01653.
    PubMed     Abstract available
    
    
    
87. KATZ D, Feldhamer I, Wolff-Sagy Y, Goldvaser H, et al
    Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-gene recurrence score (> 25): a 10-year follow-up in a real-world cohort.
    Breast Cancer. 2024 Nov 27. doi: 10.1007/s12282-024-01652.
    PubMed     Abstract available
    
    
    
88. GUO R, Wang P
    The complex role of regulatory cells in breast cancer: implication for immunopathogenesis and immunotherapy.
    Breast Cancer. 2024 Nov 26. doi: 10.1007/s12282-024-01654.
    PubMed     Abstract available
    
    
    
89. XU Q, Li X, Yuan Y, Hu Z, et al
    Development and validation of a predictive risk tool for VTE in women with breast cancer under chemotherapy: a cohort study in China.
    Breast Cancer. 2024 Nov 16. doi: 10.1007/s12282-024-01646.
    PubMed     Abstract available
    
    
    
90. NASHIMOTO M, Asano Y, Matsui H, Machida Y, et al
    Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.
    Breast Cancer. 2024;31:1010-1017.
    PubMed     Abstract available
    
    
    
91. YOSHIDA R, Kaneyasu T, Ueki A, Yamauchi H, et al
    High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.
    Breast Cancer. 2024;31:1028-1036.
    PubMed     Abstract available
    
    
    October 2024
92. TADA H, Miyashita M, Harada-Shoji N, Ebata A, et al
    Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan.
    Breast Cancer. 2024 Oct 28. doi: 10.1007/s12282-024-01639.
    PubMed     Abstract available
    
    
    
93. WANG X, Zhang X, Zhang L, Meng J, et al
    Clinical outcomes after post-operative radiotherapy for breast cancer patients presenting with ipsilateral supraclavicular metastasis: considerations on the cranial border of irradiation field.
    Breast Cancer. 2024 Oct 23. doi: 10.1007/s12282-024-01644.
    PubMed     Abstract available
    
    
    
94. TOKUNAGA E, Iwata H, Itoh M, Taira T, et al
    Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
    Breast Cancer. 2024 Oct 8. doi: 10.1007/s12282-024-01640.
    PubMed     Abstract available
    
    
    
95. HAO J, Remis A, Zhu D, Yao Y, et al
    Mirror therapy for patients with breast cancer: A systematic review and meta-analysis.
    Breast Cancer. 2024 Oct 5. doi: 10.1007/s12282-024-01642.
    PubMed     Abstract available
    
    
    
96. TAKATORI-SHIRAKAMI Y, Saito M, Yokoyama K
    Economic impact of screening on postdiagnosis work productivity in Japanese women with breast cancer: a life-table modeling approach.
    Breast Cancer. 2024 Oct 4. doi: 10.1007/s12282-024-01637.
    PubMed     Abstract available
    
    
    
97. KAWAI Y, Nagayama A, Miyao K, Takeuchi M, et al
    A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer.
    Breast Cancer. 2024 Oct 1. doi: 10.1007/s12282-024-01641.
    PubMed     Abstract available
    
    
    September 2024
98. KWON MR, Ko EY, Lee JE, Han BK, et al
    Prediction model for individualized precision surgery in breast cancer patients with complete response on MRI and residual calcifications on mammography after neoadjuvant chemotherapy.
    Breast Cancer. 2024 Sep 30. doi: 10.1007/s12282-024-01638.
    PubMed     Abstract available
    
    
    
99. HUANG Q, Wang J, Ning H, Liu W, et al
    Integrin beta1 in breast cancer: mechanisms of progression and therapy.
    Breast Cancer. 2024 Sep 30. doi: 10.1007/s12282-024-01635.
    PubMed     Abstract available
    
    
    
100. MICHAELI JC, Michaeli T, Trapani D, Albers S, et al
     Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
     Breast Cancer. 2024 Sep 25. doi: 10.1007/s12282-024-01634.
     PubMed     Abstract available
     
     
     
101. ABE T, Kataoka A, Uehiro N, Yoshida N, et al
     Desire for pregnancy and fertility preservation in young patients with breast cancer.
     Breast Cancer. 2024 Sep 25. doi: 10.1007/s12282-024-01633.
     PubMed     Abstract available
     
     
     
102. ENDO Y, Kotani H, Tamura N, Tanaka K, et al
     Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy.
     Breast Cancer. 2024 Sep 23. doi: 10.1007/s12282-024-01630.
     PubMed     Abstract available
     
     
     
103. NAKAYAMA T, Niikura N, Yamanaka T, Yamamoto M, et al
     Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
     Breast Cancer. 2024 Sep 20. doi: 10.1007/s12282-024-01632.
     PubMed    
     
     
     
104. WANG RJ, Liu HY, Guo LF, Yu D, et al
     21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer.
     Breast Cancer. 2024 Sep 19. doi: 10.1007/s12282-024-01636.
     PubMed     Abstract available
     
     
     
105. JITWATCHARAKOMOL T, Setakornnukul J, Chuthatisith S, Ratanawichitrasin A, et al
     Non-irradiated area of intraoperative radiotherapy with electron technique: outcomes and pattern of failure in early-stage breast cancer from a single-center, registry study.
     Breast Cancer. 2024 Sep 10. doi: 10.1007/s12282-024-01624.
     PubMed     Abstract available
     
     
     
106. SASADA S, Kumamaru H, Hayashi N, Kinukawa N, et al
     Impact of immediate breast reconstruction on perioperative therapy: insights from a Japanese Nationwide Registry.
     Breast Cancer. 2024;31:909-916.
     PubMed     Abstract available
     
     
     
107. MIYAZAWA K, Satake T, Muto M, Tsunoda Y, et al
     Delayed breast reconstruction with autologous free flap after radiation therapy: vascular complications and aesthetic outcomes.
     Breast Cancer. 2024;31:798-806.
     PubMed     Abstract available
     
     
     
108. BELLINI C, Pugliese F, Bicchierai G, Amato F, et al
     Contrast-enhanced mammography in the management of breast architectural distortions and avoidance of unnecessary biopsies.
     Breast Cancer. 2024;31:851-857.
     PubMed     Abstract available
     
     
     
109. SEKI H, Sasada S, Shien T
     Reply to the Letter to the editor "Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?".
     Breast Cancer. 2024 Sep 1. doi: 10.1007/s12282-024-01629.
     PubMed    
     
     
     August 2024
110. CHANG YT, Hong ZJ, Tsai HH, Feng AC, et al
     Hub metastatic gene signature and risk score of breast cancer patients with small tumor sizes using WGCNA.
     Breast Cancer. 2024 Aug 27. doi: 10.1007/s12282-024-01627.
     PubMed     Abstract available
     
     
     
111. GANATRA H, Tan JK, Simmons A, Bigogno CM, et al
     Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape.
     Breast Cancer. 2024 Aug 27. doi: 10.1007/s12282-024-01628.
     PubMed     Abstract available
     
     
     
112. KITADAI R, Shimoi T, Yazaki S, Okuma HS, et al
     Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
     Breast Cancer. 2024 Aug 14. doi: 10.1007/s12282-024-01617.
     PubMed     Abstract available
     
     
     
113. WATANABE M, Fujiki S, Okura Y, Toshikawa C, et al
     Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.
     Breast Cancer. 2024 Aug 13. doi: 10.1007/s12282-024-01623.
     PubMed     Abstract available
     
     
     
114. NAKAYAMA T, Niikura N, Yamanaka T, Yamamoto M, et al
     Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
     Breast Cancer. 2024 Aug 12. doi: 10.1007/s12282-024-01614.
     PubMed     Abstract available
     
     
     
115. RAHMANI F, Ajoudanifar H, Arbab Soleimani N, Imani Fooladi AA, et al
     Targeted therapies in HER2-positive breast cancer with receptor-redirected Arazyme-linker-Herceptin as a novel fusion protein.
     Breast Cancer. 2024 Aug 9. doi: 10.1007/s12282-024-01625.
     PubMed     Abstract available
     
     
     
116. RUIZ JI, Lei X, Chi-Fang W, Giordano SH, et al
     Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors.
     Breast Cancer. 2024 Aug 8. doi: 10.1007/s12282-024-01618.
     PubMed     Abstract available
     
     
     
117. NAKAMURA M, Fujisawa T, Oyoshi H, Zhou Y, et al
     Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC).
     Breast Cancer. 2024 Aug 8. doi: 10.1007/s12282-024-01626.
     PubMed     Abstract available
     
     
     
118. CHEN YA, Lai HW, Su HC, Loh EW, et al
     Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data.
     Breast Cancer. 2024 Aug 1. doi: 10.1007/s12282-024-01622.
     PubMed     Abstract available
     
     
     July 2024
119. UEZONO H, Onoe T, Shikama N, Ono Y, et al
     Uptake of ultra-hypofractionated radiation therapy following breast-conserving surgery among patients with early-stage breast cancer: a multi-institutional questionnaire survey.
     Breast Cancer. 2024 Jul 24. doi: 10.1007/s12282-024-01621.
     PubMed     Abstract available
     
     
     
120. ALTUNDAG K
     Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?
     Breast Cancer. 2024 Jul 20. doi: 10.1007/s12282-024-01620.
     PubMed    
     
     
     
121. HU Z, Lai C, Liu H, Man J, et al
     Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort.
     Breast Cancer. 2024 Jul 19. doi: 10.1007/s12282-024-01619.
     PubMed     Abstract available
     
     
     
122. SHIBATA A, Tamura N, Kinowaki K, Nishikawa A, et al
     Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
     Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01616.
     PubMed     Abstract available
     
     
     
123. HOSONAGA M, Habano E, Arakawa H, Kaneko K, et al
     Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
     Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01612.
     PubMed     Abstract available
     
     
     
124. PINELLI F, Barbani F, Defilippo B, Fundaro A, et al
     Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-port.
     Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01608.
     PubMed     Abstract available
     
     
     
125. NAKAMOTO S, Iwamoto T, Taira N, Kajiwara Y, et al
     The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10.
     Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01610.
     PubMed     Abstract available
     
     
     
126. WEI JF, Li F, Lin JW, Dou ZA, et al
     Development and validation of a neoadjuvant chemotherapy pathological complete remission model based on Reg IV expression in breast cancer tissues: a clinical retrospective study.
     Breast Cancer. 2024 Jul 8. doi: 10.1007/s12282-024-01609.
     PubMed     Abstract available
     
     
     
127. LUO Y, Chen X, Lv R, Li Q, et al
     Breast-conserving surgery versus modified radical mastectomy in T1-2N3M0 stage breast cancer: a propensity score matching analysis.
     Breast Cancer. 2024 Jul 8. doi: 10.1007/s12282-024-01611.
     PubMed     Abstract available
     
     
     
128. KOYAMA Y, Nakashima K, Orihara S, Tsunoda H, et al
     Inter- and intra-observer variability of qualitative visual breast-composition assessment in mammography among Japanese physicians: a first multi-institutional observer performance study in Japan.
     Breast Cancer. 2024;31:671-683.
     PubMed     Abstract available
     
     
     
129. MAITA KC, Avila FR, Torres-Guzman RA, Garcia JP, et al
     The usefulness of artificial intelligence in breast reconstruction: a systematic review.
     Breast Cancer. 2024;31:562-571.
     PubMed     Abstract available
     
     
     
130. KATO S, Mori H, Saiga M, Watanabe S, et al
     Nipple-areolar complex malposition in breast reconstruction after nipple-sparing mastectomy: a multi-institutional retrospective observational study in Japan.
     Breast Cancer. 2024;31:649-658.
     PubMed     Abstract available
     
     
     June 2024
131. WANG B, Chu H, Wei S, Hsu H, et al
     Exploration of treatment strategies and susceptibility gene of postoperative nausea and vomiting in breast cancer patients: a randomised controlled trial.
     Breast Cancer. 2024 Jun 19. doi: 10.1007/s12282-024-01606.
     PubMed     Abstract available
     
     
     
132. SEKI H, Ogiya A, Nagura N, Shimo A, et al
     Prognosis of isolated locoregional recurrence after early breast cancer with immediate breast reconstruction surgery: a retrospective multi?institutional study.
     Breast Cancer. 2024 Jun 19. doi: 10.1007/s12282-024-01607.
     PubMed     Abstract available
     
     
     
133. YAMASHITA T, Sohn JH, Tokunaga E, Niikura N, et al
     Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
     Breast Cancer. 2024 Jun 17. doi: 10.1007/s12282-024-01600.
     PubMed     Abstract available
     
     
     
134. HUANG Y, Ke C, Cai J, Wei X, et al
     Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer.
     Breast Cancer. 2024 Jun 15. doi: 10.1007/s12282-024-01605.
     PubMed     Abstract available
     
     
     
135. TELLI ML, Litton JK, Beck JT, Jones JM, et al
     Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
     Breast Cancer. 2024 Jun 13. doi: 10.1007/s12282-024-01603.
     PubMed     Abstract available
     
     
     
136. KITANO S, Tsunashima R, Kato C, Watanabe A, et al
     Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
     Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01602.
     PubMed     Abstract available
     
     
     
137. PURJA S, Nguyen DT, Kim E
     Breast cancer epigenetics: current and evolving treatment.
     Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01601.
     PubMed     Abstract available
     
     
     
138. CHEN Y, Zhou Y, Chen J, Yang J, et al
     Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression.
     Breast Cancer. 2024 Jun 4. doi: 10.1007/s12282-024-01574.
     PubMed     Abstract available
     
     
     May 2024
139. MUR-GIMENO E, Coll M, Yuguero-Ortiz A, Navarro M, et al
     Comparison of water- vs. land-based exercise for improving functional capacity and quality of life in patients living with and beyond breast cancer (the AQUA-FiT study): a randomized controlled trial.
     Breast Cancer. 2024 May 30. doi: 10.1007/s12282-024-01596.
     PubMed     Abstract available
     
     
     
140. TENG L, Du J, Yan S, Xu P, et al
     A novel nomogram and survival analysis for different lymph node status in breast cancer based on the SEER database.
     Breast Cancer. 2024 May 27. doi: 10.1007/s12282-024-01591.
     PubMed     Abstract available
     
     
     
141. OKUYAMA H, Takada F, Taira N, Nakamura S, et al
     A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy.
     Breast Cancer. 2024 May 26. doi: 10.1007/s12282-024-01592.
     PubMed     Abstract available
     
     
     
142. KATARIA M, Gupta N, Kumar A, Bhoriwal S, et al
     Assessing the effectiveness of high frequency repetitive transcranial magnetic stimulation for post-mastectomy pain in breast cancer patients: A randomized controlled trial.
     Breast Cancer. 2024 May 26. doi: 10.1007/s12282-024-01598.
     PubMed     Abstract available
     
     
     
143. FRANCESCHI BT, Bezerra PHA, Torqueti MR
     Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.
     Breast Cancer. 2024 May 23. doi: 10.1007/s12282-024-01590.
     PubMed     Abstract available
     
     
     
144. JEZEQUEL P, Lasla H, Gouraud W, Basseville A, et al
     Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
     Breast Cancer. 2024 May 22. doi: 10.1007/s12282-024-01597.
     PubMed     Abstract available
     
     
     
145. ALTUNDAG K
     Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density.
     Breast Cancer. 2024 May 18. doi: 10.1007/s12282-024-01595.
     PubMed    
     
     
     
146. DURAN S, Varol U, Tekir O, Soyturk AH, et al
     Resilience's impact on quality of life and post-traumatic growth in breast cancer patients during treatment.
     Breast Cancer. 2024 May 17. doi: 10.1007/s12282-024-01594.
     PubMed     Abstract available
     
     
     
147. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
     Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
     Breast Cancer. 2024 May 12. doi: 10.1007/s12282-024-01589.
     PubMed    
     
     
     
148. BAO YQ, Yu TH, Huang W, Mao QF, et al
     Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients.
     Breast Cancer. 2024 May 5. doi: 10.1007/s12282-024-01588.
     PubMed     Abstract available
     
     
     
149. VAN ROOIJ JAF, Bijkerk E, van der Hulst RRJW, Tuinder SMH, et al
     The influence of a previous implant-based breast reconstruction on postoperative sensation of the deep inferior epigastric artery perforator flap.
     Breast Cancer. 2024;31:456-466.
     PubMed     Abstract available
     
     
     
150. NOGI H, Ogiya A, Ishitobi M, Yamauchi C, et al
     Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
     Breast Cancer. 2024;31:507-518.
     PubMed     Abstract available
     
     
     
151. CH'NG ES
     Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.
     Breast Cancer. 2024;31:496-506.
     PubMed     Abstract available
     
     
     
152. TSUCHIDA Y, Niikura N, Chishima T, Mizuno M, et al
     Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX(R) test data: a retrospective multicenter study in Japan.
     Breast Cancer. 2024;31:401-408.
     PubMed     Abstract available
     
     
     
153. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
     Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
     Breast Cancer. 2024;31:536-538.
     PubMed    
     
     
     April 2024
154. SHIMOMURA A, Sagara Y, Koto R, Fujiwara M, et al
     Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.
     Breast Cancer. 2024 Apr 29. doi: 10.1007/s12282-024-01572.
     PubMed     Abstract available
     
     
     
155. KAWAMOTO H, Tsugawa K, Furuya Y, Sakamaki K, et al
     Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan.
     Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01584.
     PubMed     Abstract available
     
     
     
156. LEE SJ, Cha CD, Hong H, Choi YY, et al
     Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis.
     Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01586.
     PubMed     Abstract available
     
     
     
157. YANG PJ, Tsai EM, Hou MF, Lee YJ, et al
     Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors.
     Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01579.
     PubMed     Abstract available
     
     
     
158. YOSHINAMI T
     Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy.
     Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01571.
     PubMed     Abstract available
     
     
     
159. ALTUNDAG K
     Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients.
     Breast Cancer. 2024 Apr 22. doi: 10.1007/s12282-024-01587.
     PubMed    
     
     
     
160. SHANG Y, Wang X, Liu Y, Cheng W, et al
     Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
     Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01583.
     PubMed     Abstract available
     
     
     
161. NA S, Kim M, Park Y, Kwon HJ, et al
     Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.
     Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01585.
     PubMed     Abstract available
     
     
     
162. YOSHINAMI T, Nagai SE, Hattori M, Okamura T, et al
     Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or seco
     Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575.
     PubMed     Abstract available
     
     
     
163. ROUSSET-JABLONSKI C, Lortal B, Lantheaume S, Arnould L, et al
     French national survey on breast cancer care: caregiver and patient views.
     Breast Cancer. 2024 Apr 18. doi: 10.1007/s12282-024-01576.
     PubMed     Abstract available
     
     
     
164. ZHANG HP, Jiang RY, Zhu JY, Sun KN, et al
     PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
     Breast Cancer. 2024 Apr 17. doi: 10.1007/s12282-024-01567.
     PubMed     Abstract available
     
     
     
165. TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
     Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
     Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
     PubMed     Abstract available
     
     
     
166. DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
     Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
     Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
     PubMed     Abstract available
     
     
     
167. SUZUKI K, Morishita S, Nakano J, Okayama T, et al
     Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.
     Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
     PubMed     Abstract available
     
     
     
168. WATANABE A, Tsunashima R, Kato C, Kitano S, et al
     Investigation of recurrence prediction ability of EndoPredict((R)) using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to FFPE
     Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
     PubMed     Abstract available
     
     
     
169. YOSHIMURA M, Yamauchi C, Sanuki N, Hamamoto Y, et al
     The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.
     Breast Cancer. 2024 Apr 5. doi: 10.1007/s12282-024-01568.
     PubMed     Abstract available
     
     
     
170. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
     The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
     Breast Cancer. 2024 Apr 3. doi: 10.1007/s12282-024-01566.
     PubMed     Abstract available
     
     
     
171. LIN D, Sturgeon KM, Muscat JE, Zhou S, et al
     Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
     Breast Cancer. 2024 Apr 2. doi: 10.1007/s12282-024-01569.
     PubMed     Abstract available
     
     
     
172. YE JH, Yu J, Huang MY, Mo YM, et al
     The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
     Breast Cancer. 2024 Apr 1. doi: 10.1007/s12282-024-01553.
     PubMed     Abstract available
     
     
     March 2024
173. OCHIYA T, Hashimoto K, Shimomura A
     Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer.
     Breast Cancer. 2024 Mar 30. doi: 10.1007/s12282-024-01563.
     PubMed     Abstract available
     
     
     
174. NARUI K, Satake T, Ishikawa T, Muto M, et al
     Endoscopic mastectomy followed by immediate breast reconstruction with fat grafting for breast cancer.
     Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01561.
     PubMed     Abstract available
     
     
     
175. HASHIMOTO K, Ochiya T, Shimomura A
     Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management.
     Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01562.
     PubMed     Abstract available
     
     
     
176. VO K, Ladbury C, Yoon S, Bazan J, et al
     Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
     Breast Cancer. 2024 Mar 20. doi: 10.1007/s12282-024-01560.
     PubMed     Abstract available
     
     
     
177. OHMURA H, Hanamura F, Okumura Y, Ando Y, et al
     Liquid biopsy for breast cancer and other solid tumors: a review of recent advances.
     Breast Cancer. 2024 Mar 16. doi: 10.1007/s12282-024-01556.
     PubMed     Abstract available
     
     
     
178. HU X
     The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
     Breast Cancer. 2024 Mar 14. doi: 10.1007/s12282-024-01557.
     PubMed     Abstract available
     
     
     
179. LI G, Lin X, Wang X, Cai L, et al
     Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB.
     Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01554.
     PubMed     Abstract available
     
     
     
180. KANG D, Park S, Kim HJ, Lee J, et al
     Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile.
     Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01559.
     PubMed     Abstract available
     
     
     
181. KIDA K, Yamada A, Shimada K, Narui K, et al
     A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
     Breast Cancer. 2024 Mar 8. doi: 10.1007/s12282-024-01551.
     PubMed     Abstract available
     
     
     
182. OBA K, Adachi M, Kobayashi T, Takaya E, et al
     Deep learning model to predict Ki-67 expression of breast cancer using digital breast tomosynthesis.
     Breast Cancer. 2024 Mar 7. doi: 10.1007/s12282-024-01549.
     PubMed     Abstract available
     
     
     
183. HATTORI M, Honma N, Nagai S, Narui K, et al
     Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
     Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01550.
     PubMed     Abstract available
     
     
     
184. KASAHARA M, Kanematsu S, Tanaka Y, Okazaki S, et al
     Clinical benefits of tomosynthesis-guided vacuum assisted breast biopsy: a comparison with stereotactic vacuum assisted biopsy.
     Breast Cancer. 2024;31:329-334.
     PubMed     Abstract available
     
     
     
185. WU X, Gui Y, Liu J, Li S, et al
     Patient-reported outcomes of mesh in minimally invasive (laparoscopic/robot-assisted) immediate subpectoral prosthesis breast reconstruction: a retrospective study.
     Breast Cancer. 2024;31:243-251.
     PubMed     Abstract available
     
     
     
186. WONG HH, Cojocaru E, Watkins J, James S, et al
     Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.
     Breast Cancer. 2024;31:272-282.
     PubMed     Abstract available
     
     
     
187. AOYAMA Y, Hoshino E, Shimomura A, Shimizu C, et al
     Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
     Breast Cancer. 2024;31:234-242.
     PubMed     Abstract available
     
     
     
188. CHEN BF, Tsai YF, Lien PJ, Lin YS, et al
     Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
     Breast Cancer. 2024;31:217-227.
     PubMed     Abstract available
     
     
     
189. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
     The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening.
     Breast Cancer. 2024;31:228-233.
     PubMed     Abstract available
     
     
     February 2024
190. PARIJA M, Prakash S, Krishna BM, Dash S, et al
     SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor beta.
     Breast Cancer. 2024 Feb 29. doi: 10.1007/s12282-024-01555.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.